CollPlant Biotechnologies Ltd. - Ordinary Shares (CLGN)

The firm reported revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI.

CollPlant stock plunges 10.7% after Q3 2025 earnings miss, with revenue of $80k far below the $4.94 million estimate.

CollPlant (CLGN) Q2 2025 results miss analyst estimates, with revenue of $180K far below expectations. Shares fell in pre-market trading on the earnings disappointment.